Immune Checkpoints in Cancers: From Signaling to the Clinic

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Sep 28

PMID 34572799

Citations 23

Authors

Celine Pisibon

Amira Ouertani

Corine Bertolotto

Robert Ballotti

Yann Cheli

Affiliations

Soon will be listed here.

Abstract

The immune system is known to help fight cancers. Ten years ago, the first immune checkpoint inhibitor targeting CTLA4 was approved by the FDA to treat patients with metastatic melanoma. Since then, immune checkpoint therapies have revolutionized the field of oncology and the treatment of cancer patients. Numerous immune checkpoint inhibitors have been developed and tested, alone or in combination with other treatments, in melanoma and other cancers, with overall clear benefits to patient outcomes. However, many patients fail to respond or develop resistance to these treatments. It is therefore essential to decipher the mechanisms of action of immune checkpoints and to understand how immune cells are affected by signaling to be able to understand and overcome resistance. In this review, we discuss the signaling and effects of each immune checkpoint on different immune cells and their biological and clinical relevance. Restoring the functionality of T cells and their coordination with other immune cells is necessary to overcome resistance and help design new clinical immunotherapy strategies. In this respect, NK cells have recently been implicated in the resistance to anti-PD1 evoked by a protein secreted by melanoma, ITGBL1. The complexity of this network will have to be considered to improve the efficiency of future immunotherapies and may lead to the discovery of new immune checkpoints.

Citing Articles

Toxicity of Cancer Immunotherapies in Older Patients: Does Age Make a Difference?.

Cil E, Gomes F Drugs Aging. 2024; 41(10):787-794.

PMID: 39368044 DOI: 10.1007/s40266-024-01149-2.

Identification of novel disulfidptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of skin cutaneous melanoma patients.

Cheng S, Wang X, Yang S, Liang J, Song C, Zhu Q Skin Res Technol. 2024; 30(7):e13814.

PMID: 38924611 PMC: 11197043. DOI: 10.1111/srt.13814.

Animal model considerations for chordoma research: reproducing the tumor microenvironment with humanized mice.

Campilan B, Schroeder C, Sagaityte E, Arditi J, Leary O, Ziya L Gokaslan Front Oncol. 2024; 14:1330254.

PMID: 38544830 PMC: 10965562. DOI: 10.3389/fonc.2024.1330254.

Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents.

Gurtatta R, Whalen S, Ray Jr C Semin Intervent Radiol. 2024; 41(1):84-91.

PMID: 38495256 PMC: 10940041. DOI: 10.1055/s-0043-1778660.

Complement factor H: a novel innate immune checkpoint in cancer immunotherapy.

Saxena R, Gottlin E, Campa M, Bushey R, Guo J, Patz Jr E Front Cell Dev Biol. 2024; 12:1302490.

PMID: 38389705 PMC: 10883309. DOI: 10.3389/fcell.2024.1302490.

References

Bright R, Coventry B, Eardley-Harris N, Briggs N . Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients. J Immunother. 2016; 40(1):21-30. DOI: 10.1097/CJI.0000000000000149. View

Chaudhry A, Samstein R, Treuting P, Liang Y, Pils M, Heinrich J . Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011; 34(4):566-78. PMC: 3088485. DOI: 10.1016/j.immuni.2011.03.018. View

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher I, Sander C . Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207(10):2175-86. PMC: 2947081. DOI: 10.1084/jem.20100637. View

Jansson A, Barnes E, Klenerman P, Harlen M, Sorensen P, Davis S . A theoretical framework for quantitative analysis of the molecular basis of costimulation. J Immunol. 2005; 175(3):1575-85. DOI: 10.4049/jimmunol.175.3.1575. View

Chen Y, Wen R, Yang S, Schuman J, Zhang E, Yi T . Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem. 2003; 278(19):16520-7. DOI: 10.1074/jbc.M210572200. View

Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, Maigret B . Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A. 1997; 94(11):5744-9. PMC: 20850. DOI: 10.1073/pnas.94.11.5744. View

Ndhlovu L, Lopez-Verges S, Barbour J, Jones R, Jha A, Long B . Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012; 119(16):3734-43. PMC: 3335380. DOI: 10.1182/blood-2011-11-392951. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Taylor S, Huang Y, Mallett G, Stathopoulou C, Felizardo T, Sun M . PD-1 regulates KLRG1 group 2 innate lymphoid cells. J Exp Med. 2017; 214(6):1663-1678. PMC: 5461001. DOI: 10.1084/jem.20161653. View

10.

Mastrangeli R, Micangeli E, Donini S . Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (gene-capture PCR). Anal Biochem. 1996; 241(1):93-102. DOI: 10.1006/abio.1996.0382. View

11.

Huang Y, Zhu C, Kondo Y, Anderson A, Gandhi A, Russell A . CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2014; 517(7534):386-90. PMC: 4297519. DOI: 10.1038/nature13848. View

12.

Patsoukis N, Sari D, Boussiotis V . PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle. 2012; 11(23):4305-9. PMC: 3552912. DOI: 10.4161/cc.22135. View

13.

Rota G, Niogret C, Dang A, Barros C, Fonta N, Alfei F . Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. Cell Rep. 2018; 23(1):39-49. DOI: 10.1016/j.celrep.2018.03.026. View

14.

Zhou X, Li W, Wu Y, Han L, Cao X, Yang X . Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth by Suppressing the Function of NK and CD8 T Cells. Front Immunol. 2018; 9:2821. PMC: 6281988. DOI: 10.3389/fimmu.2018.02821. View

15.

Sabatos C, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng X . Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003; 4(11):1102-10. DOI: 10.1038/ni988. View

16.

Haro M, Littrell C, Yin Z, Huang X, Haas K . PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors. Cancer Immunol Res. 2016; 4(12):1027-1037. PMC: 5373664. DOI: 10.1158/2326-6066.CIR-16-0184. View

17.

Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K . B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019; 10(1):4186. PMC: 6744450. DOI: 10.1038/s41467-019-12160-2. View

18.

Iouzalen N, Andreae S, Hannier S, Triebel F . LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway. Eur J Immunol. 2001; 31(10):2885-91. DOI: 10.1002/1521-4141(2001010)31:10<2885::aid-immu2885>3.0.co;2-2. View

19.

Juno J, Stalker A, Waruk J, Oyugi J, Kimani M, Plummer F . Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment. Retrovirology. 2015; 12:17. PMC: 4332911. DOI: 10.1186/s12977-015-0142-z. View

20.

Baixeras E, Huard B, Miossec C, JITSUKAWA S, Martin M, Hercend T . Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992; 176(2):327-37. PMC: 2119326. DOI: 10.1084/jem.176.2.327. View